Figure 2 - uploaded by Tadashi Terui
Content may be subject to copyright.
Source publication
To clarify the prevalence of skin disorders among dermatology patients in Japan, a nationwide, cross-sectional, seasonal, multicenter study was conducted in 69 university hospitals, 45 district-based pivotal hospitals, and 56 private clinics (170 clinics in total). In each clinic, information was collected on the diagnosis, age, and gender of all o...
Contexts in source publication
Context 1
... ⁄ angioedema showed a triphasic distribution pattern (Fig. 1c), whereas viral warts peaked at 6-15 years of age (Fig. 1d). Psoriasis peaked at 56-65 years of age (Fig. 2a). The age distribution for contact dermatitis was somewhat evenly dispersed (Fig. 2b). The peak age for acne was 16-25 years ( Fig. 2c), whereas that for seborrheic dermatitis was 71-75 ( Fig. 2d). Hand eczema was distributed evenly in adults (Fig. 3a). The peak age for alopecia areata was 31-35 years (Fig. 3b). Herpes zoster ⁄ ...
Context 2
... ⁄ angioedema showed a triphasic distribution pattern (Fig. 1c), whereas viral warts peaked at 6-15 years of age (Fig. 1d). Psoriasis peaked at 56-65 years of age (Fig. 2a). The age distribution for contact dermatitis was somewhat evenly dispersed (Fig. 2b). The peak age for acne was 16-25 years ( Fig. 2c), whereas that for seborrheic dermatitis was 71-75 ( Fig. 2d). Hand eczema was distributed evenly in adults (Fig. 3a). The peak age for alopecia areata was 31-35 years (Fig. 3b). Herpes zoster ⁄ zosterassociated pain and prurigo were prominent in elderly patients (Fig. 3c,d). Epidermal ...
Context 3
... ⁄ angioedema showed a triphasic distribution pattern (Fig. 1c), whereas viral warts peaked at 6-15 years of age (Fig. 1d). Psoriasis peaked at 56-65 years of age (Fig. 2a). The age distribution for contact dermatitis was somewhat evenly dispersed (Fig. 2b). The peak age for acne was 16-25 years ( Fig. 2c), whereas that for seborrheic dermatitis was 71-75 ( Fig. 2d). Hand eczema was distributed evenly in adults (Fig. 3a). The peak age for alopecia areata was 31-35 years (Fig. 3b). Herpes zoster ⁄ zosterassociated pain and prurigo were prominent in elderly patients (Fig. 3c,d). Epidermal cysts occurred in adults of all ages (Fig. 4a). ...
Context 4
... showed a triphasic distribution pattern (Fig. 1c), whereas viral warts peaked at 6-15 years of age (Fig. 1d). Psoriasis peaked at 56-65 years of age (Fig. 2a). The age distribution for contact dermatitis was somewhat evenly dispersed (Fig. 2b). The peak age for acne was 16-25 years ( Fig. 2c), whereas that for seborrheic dermatitis was 71-75 ( Fig. 2d). Hand eczema was distributed evenly in adults (Fig. 3a). The peak age for alopecia areata was 31-35 years (Fig. 3b). Herpes zoster ⁄ zosterassociated pain and prurigo were prominent in elderly patients (Fig. 3c,d). Epidermal cysts occurred in adults of all ages (Fig. 4a). Vitiligo vulgaris and drug eruption ⁄ toxicoderma were ...
Citations
... 21 , at 0.5%. However, a previous multicenter cross-sectional study conducted with 170 health centers, with information from hospitalized and outpatient patients, found a higher prevalence of 1.68%, with a higher frequency between the seventh and eighth decades of life 14 . ...
... 21 , con un 0.5%. No obstante, un estudio previo transversal multicéntrico en 170 instituciones de salud, con información de pacientes hospitalizados y ambulatorios, encontró una prevalencia mayor, del 1.68%, con una mayor frecuencia entre la séptima y la octava décadas de la vida 14 . ...
... As of the early 1970s, AA prevalence in the USA was estimated to be between 0.1 and 0.2%, with a lifetime prevalence rate of 1.7%. This population was followed up from 1990 to 2009, and the cumulative incidence increased almost linearly with age, with AA occurring at a 2.1% lifetime incidence rate [6] Greece, Japan and Saudi Arabia all reported high prevalences of AA as well, at 1.3, 2.5 and 2.3%, respectively [27][28][29]. In a study, the family history of AA patients should be considered as their siblings, parents and children all face a lifetime risk of 7.1, 7.8 and 5.7%, respectively [30]. ...
Alopecia areata (AA) is a kind of alopecia that affects hair follicles and nails. It typically comes with round patches and is a type of nonscarring hair loss. Various therapies are accessible for the management and treatment of AA, including topical, systemic and injectable modalities. It is a very complex type of autoimmune disease and is identified as round patches of hair loss and may occur at any age. This review paper highlights the epidemiology, clinical features, pathogenesis and new treatment options for AA, with a specific emphasis on nanoparticulate drug-delivery systems. By exploring these innovative treatment approaches, researchers aim to enhance the effectiveness and targeted delivery of therapeutic agents, ultimately improving outcomes for individuals living with AA.
... [10] reported that scabies, followed by pediculosis were more common among parasitic diseases [10]. A study conducted in Japan reported that scabies showed predominantly higher rates compared to other parasitic diseases [11]. ...
Dermatological conditions are a major health problem and one of the important causes of medical service utilization. It is important to determine the clinical-epidemiological factors influencing the development of dermatological conditions. This study aimed to determine the clinic-epidemiological characteristics of patients with skin diseases in a tertiary care center in Ajman, UAE. A record-based study among 2091 cases presented in the outpatient department from 2020 to 2021 was recorded using a proforma and duplication was eliminated. SPSS 28 was used for the statistical analysis. A chi-square test was performed to find the association between variables, and a p-value ≤0.05 was considered statistically significant. Among the total number of participants in this study (N=2091), 1084 (51.8%) were females and 1007 (48.2%) were males. Out of the total, 847 (40.5%) participants visited the hospital in the summer, 512 (24.5%) in the winter, and the rest in the spring and autumn. According to age, the majority (53.1%) were older than 30 years of age. The most diagnosed conditions were dermatitis (49.4%), followed by other skin infections. A majority of the study participants were diagnosed during the summer season (40.5%), were females, (51.8%), and belonged to the > 30 years' age category (53.1%). Dermatitis, papulosquamous disorders, acne, tumors, and others were seen to have a significant seasonal variation. Papulosquamous disorders, infestations, acne, sexually transmitted disorders, other skin infections, and others showed a significant association with gender. Dermatitis, papulosquamous disorder, acne, hair disorder, tumors, other skin infections, and others were seen to have a significant association with age. This research demonstrates the significance of seasonal variations in developing dermatological conditions. This can help skin care providers advise their patients to apply prevention strategies to avoid the occurrence and recurrence of dermatological conditions.
... Many medical conditions display seasonality in terms of presenting with a first episode or exacerbation of an existing medical problem [6][7][8][9][10][11]. Clinical observations pointed to the same pattern in psoriasis with deterioration or first episodes starting mainly in cold months [12][13][14]. This pattern was not however observed by all authors, citing multifactorial nature of the disease [15,16]. Recently, a review on seasonal variation of psoriasis in Northern and Central Europe revealed that 50% of patients showed no difference in the severity of their ...
Introduction: It is well known that biological medications acting on selected elements of the immune response are highly effective in psoriasis treatment. It is a common perception that psoriasis is a seasonal disorder with improvement in warmer months, however it has not been unequivocally confirmed. It is not known whether the time of year of starting systematic therapy for psoriasis influences treatment outcomes. Material and methods: Changes in psoriasis severity scores during treatment with biologics were investigated. The scores were recorded for 62 patients with moderate to severe psoriasis at the beginning, after 1, 4 and 7 months of the therapy. Patients were divided into two groups: those beginning the treatment in the cold period of the year (November-March) and in the warm period (May-September). The seasonal groups were also divided into subgroups according to the type of biologics used: interleukin inhibitors and tumor necrosis factor α (TNF-α) inhibitors. Results of the treatment were analysed using standard statistical tests of differences between samples. Results: After 1 and 4 months of the therapy, better efficacy of interleukin inhibitors was found in patients starting treatment in summer. The course of psoriasis improvement in patients taking TNF-α inhibitors resulted in consistent improvement regardless of the season. The outcome of the treatment after 7 months was similar for both seasonal groups and types of biologics used. Conclusions: Our understanding of the effectiveness of the treatments depending on the time of the year combined with the type of biologics used, may further improve results of the therapy.
... The literature on the epidemiological distribution by sex shows conflicting results, as female or male predominance was reported [5]. Other sex differences include age, AA severity, and other symptoms (affecting nails) [28][29][30][31][32][33][34][35][36]. ...
Background: Alopecia areata is a skin disease that affects patients’ quality of life and social participation. Objective: To quantify the economic burden of alopecia areata and to map health services utilization among patients with alopecia areata.Materials and methods: Prospective and retrospective data sources, using both top-down and bottom-up approaches to estimate direct and indirect costs and to map health service utilization associated with alopecia areata in Romania in 2022.Results: In our study, the total cost of alopecia areata in Romania for 2022 was estimated at 46.289 million EUR for adult patients and 1.89 million EUR for pediatric patients, encompassing both mild and severe cases. The breakdown reveals that both mild and severe cases incurred the highest costs due to associated expenses, medical services, and treatment. As for children, the highest alopecia-related expenses were represented by associated expenses and treatment costs (for both severity levels).Conclusion: This is the first study to quantify the burden of alopecia areata in Romania. Additional studies are needed due to a low sample size. However, considering our estimations based on external data sources, alopecia areata should be considered when planning health service distribution.
... In a study from Türkiye, the most common disease group was identified as dermatitis and eczema (21.8%) [8]. Dermatitis and eczema were also the most frequently reported group of skin diseases in previous studies conducted in Greece, Iraq, Japan, Saudi Arabia, and South Africa [11][12][13][14][15]. In this study, the most common disease group among the 1772 skin diseases diagnosed was the disorders of skin appendages (30.7%). ...
Skin diseases are among the reasons for frequent hospital admissions and bring a significant burden. The aim of this study is to determine the pattern of skin diseases in our dermatology outpatient clinic in a tertiary care hospital in Türkiye. Pediatric and adult patients evaluated in our dermatology outpatient clinics for the first time were included in this cross-sectional observational designed study between January and March 2023. The characteristics of the patients, including age, gender, duration of disease, anatomic localization of the disease, and complaint counts, were recorded in the data collection form. Diagnoses were grouped according to gender, age, and complaint counts. A total of 1381 patients with 1772 skin problems were included in the study. 62.3% of the patients were female (n=860), and 37.7% (n=521) were male. The age range was between 0 and 98 years. The most common diseases were acne (18%), dermatophytosis (8.1%), viral warts (6.5%), seborrheic dermatitis (4.8%), other dermatitis (4.8%), follicular disorders (4.6%), pruritus (3.7%), scabies (3%), benign neoplasms (3%), and urticaria (3%), respectively. 23.4% of the patients (n=324) had at least two complaints. The maximum number of complaints at one visit was 5. The probability of reporting more than one complaint was higher in women and those whose first complaint was on the scalp. In this analysis to determine the patterns of skin diseases, acne, dermatophytosis, and viral warts were found to be important problems. The number of complaints at one visit may vary according to gender and localization.
... Inequalities will always be present in various kinds of allergic skin diseases, and in the current studies (61.2%) as in other studies in Taiwan, Japan, and China, a high incidence of dermatitis contact can be caused by impaired epidermal barrier function and a history of long-term exposure to various potential irritants or allergens that can increase susceptibility with age [8,14,21,28]. As a result of intrinsic and extrinsic factors, changes begin to occur with the clinical characteristics of dry, inflexible, prone skin and inadequate wound healing [19]. ...
... 26 Impetigo, which was not related to treatment, was mainly observed in pediatric patients, and is postulated to be associated with dry skin with AD in the pediatric population. 28,29 In the NCT03961529 trial, treatment-related folliculitis was observed in only two (1.0%) pediatric patients and in one adult (0.6%) patient, and all cases were mild. 26 In contrast, folliculitis is frequently observed with the use of topical tacrolimus (reported incidence of 11.7%) and TCSs. ...
Atopic dermatitis (AD) is a common chronic relapsing inflammatory skin disease. The pathogenesis of AD is complex and still not fully understood. Despite recent therapeutic developments, the current therapeutic arsenal of AD remains limited and is associated with long-term efficacy and safety issues. Therefore, new topical therapies with different mechanisms of action are required to overcome the limitations of existing treatments. Difamilast is a phosphodiesterase 4 inhibitor currently in phase 3 studies. Difamilast shows antipruritic and anti-inflammatory properties and a rapid onset of action, with significant differences in some parameters from the vehicle within 1 week of treatment. Phase 2 and 3 clinical trials have shown that difamilast ointments are effective and well tolerated in adult and pediatric patients with AD, and are expected to be used for long-term AD treatment. In 2021, difamilast was the first phosphodiesterase 4inhibitor to acquire manufacturing and marketing approval in Japan for the treatment of adult and pediatric patients (2 years of age and older) with AD. This article is a narrative review of the current literature on difamilast in the management of AD.
... 1 AD is the second most common dermatological disorder in Japan, with a prevalence of around 11% in children and 7% in adults. [2][3][4] In most patients, AD develops in early childhood and may persist into adulthood. 2,5 AD is often the precursor to other atopic diseases, such as asthma, allergic rhinitis and food allergy, also known as the atopic march, which represents the typical sequence of atopic manifestations in childhood to the development of other allergic disorders in advanced age. ...
Objectives
Atopic dermatitis (AD) is a common chronic inflammatory skin disorder in Japan. Dupilumab, a fully human monoclonal antibody, targets a shared subunit of the interleukin (IL)‐4 and IL‐13 receptors. Post‐marketing surveillance of the safety and effectiveness of dupilumab in adult AD patients was conducted in Japan, where the drug is also allowed for use in older adolescents (i.e., ≥15 years), and interim results are reported here.
Methods
This observational, multicenter study enrolled Japanese patients with AD who initiated dupilumab between July 2018–June 2020 (UMIN‐CTR Trials Registry: UMIN000032807). Baseline demographics, clinical history, medication data and dupilumab safety and effectiveness data were collected.
Results
By the data cut‐off date of March 26, 2021, information from 600 patients has been collected. All the available safety and 1‐year effectiveness data are presented. The mean (standard deviation) age was 42.0 (15.9) years, the majority (69.1%) were male, and asthma was present in 12.2%. Adverse drug reactions (ADRs) were observed in 98 patients (16.4%), including conjunctivitis (n = 40; 6.7%), conjunctivitis allergic (n = 30; 5.0%), blepharitis (n = 5; 0.8%), headache and eye pruritus (n = 4; 0.7% each) and eosinophilia (n = 3; 0.5%). Six patients experienced asthma, all of whom had a history of, or concurrent, asthma. Disease severity improved remarkably at 4 months in most patients, which was maintained up to 1 year.
Conclusion
Dupilumab appears to be a safe and effective treatment for patients aged ≥15 years with moderate‐to‐severe AD in routine clinical practice in Japan. Dupilumab was well tolerated, with no new safety signals and no new‐onset asthma.
